AAPL299.11+2.10 (+0.71%) ▲|ABBV234.85+4.84 (+2.10%) ▲|ABT90.75+2.92 (+3.32%) ▲|ACN126.82+1.99 (+1.59%) ▲|ADBE199.47+4.57 (+2.34%) ▲|AMAT586.25-53.93 (-8.42%) ▼|AMD520.90-30.73 (-5.57%) ▼|AMGN347.78+3.06 (+0.89%) ▲|AMT178.42+1.99 (+1.13%) ▲|AMZN234.44+1.65 (+0.71%) ▲|AVGO383.75-8.39 (-2.14%) ▼|AXP337.06-1.01 (-0.30%) ▼|BA218.49-2.34 (-1.06%) ▼|BAC57.79+0.42 (+0.72%) ▲|BKNG169.51+1.74 (+1.04%) ▲|BLK1,020.11-31.64 (-3.01%) ▼|BMY55.68+0.98 (+1.79%) ▲|BNY147.89+1.45 (+0.99%) ▲|BRK-B493.60+4.91 (+1.00%) ▲|C145.37-0.30 (-0.21%) ▼|CAT989.58-32.71 (-3.20%) ▼|CL91.38+2.71 (+3.05%) ▲|CMCSA22.89+0.57 (+2.53%) ▲|COF198.39-2.31 (-1.15%) ▼|COP110.28+0.58 (+0.52%) ▲|COST961.01+9.66 (+1.02%) ▲|CRM154.87+4.75 (+3.16%) ▲|CSCO121.81+0.28 (+0.23%) ▲|CVS101.33+0.03 (+0.03%) ▲|CVX176.14+1.08 (+0.61%) ▲|DE598.59+0.00 (+0.00%) ▲|DHR178.54+0.35 (+0.20%) ▲|DIS103.44+0.99 (+0.96%) ▲|DUK125.06+1.54 (+1.25%) ▲|EMR144.51-5.71 (-3.80%) ▼|FDX323.30-5.48 (-1.67%) ▼|GD349.10+5.74 (+1.67%) ▲|GE357.08+1.96 (+0.55%) ▲|GEV1,048.85-78.74 (-6.98%) ▼|GILD125.78+0.91 (+0.73%) ▲|GM80.08-0.35 (-0.44%) ▼|GOOG346.84-1.95 (-0.56%) ▼|GOOGL347.35-2.21 (-0.63%) ▼|GS1,099.08-7.29 (-0.66%) ▼|HD325.50-1.13 (-0.34%) ▼|HON224.66-3.46 (-1.51%) ▼|IBM265.84+13.62 (+5.40%) ▲|INTC133.70-7.24 (-5.14%) ▼|INTU260.76+2.99 (+1.16%) ▲|ISRG401.54-1.42 (-0.35%) ▼|JNJ237.14+5.85 (+2.53%) ▲|JPM334.13+2.65 (+0.80%) ▲|KO79.93+0.40 (+0.50%) ▲|LIN517.00+0.29 (+0.06%) ▲|LLY1,104.37+2.29 (+0.21%) ▲|LMT502.25+8.65 (+1.75%) ▲|LOW214.90+0.50 (+0.23%) ▲|LRCX370.97-38.57 (-9.42%) ▼|MA488.32+4.23 (+0.87%) ▲|MCD271.75+1.65 (+0.61%) ▲|MDLZ60.66+1.15 (+1.92%) ▲|MDT80.36+1.09 (+1.38%) ▲|META564.45+0.60 (+0.11%) ▲|MMM162.40-0.82 (-0.50%) ▼|MO71.12+1.61 (+2.32%) ▲|MRK118.74+3.26 (+2.82%) ▲|MS227.48+0.39 (+0.17%) ▲|MSFT372.72+5.38 (+1.46%) ▲|MU1,072.68-138.70 (-11.45%) ▼|NEE86.58+0.50 (+0.58%) ▲|NFLX73.19+0.31 (+0.42%) ▲|NKE42.94-0.25 (-0.58%) ▼|NOW97.36+4.35 (+4.67%) ▲|NVDA201.83-6.82 (-3.27%) ▼|ORCL168.27-6.80 (-3.88%) ▼|PEP141.06+0.35 (+0.25%) ▲|PFE25.01-0.08 (-0.30%) ▼|PG150.60+2.92 (+1.98%) ▲|PLTR118.86-0.64 (-0.54%) ▼|PM177.91+4.74 (+2.74%) ▲|QCOM201.15-20.75 (-9.35%) ▼|RTX184.92+3.09 (+1.70%) ▲|SBUX100.89+0.74 (+0.74%) ▲|SCHW93.03+1.00 (+1.09%) ▲|SO94.60+1.17 (+1.25%) ▲|SPG216.71+2.14 (+1.00%) ▲|T22.87+0.77 (+3.48%) ▲|TMO466.82+2.81 (+0.61%) ▲|TMUS183.26+3.20 (+1.78%) ▲|TSLA384.06-20.99 (-5.18%) ▼|TXN302.80-29.48 (-8.87%) ▼|UBER70.55-0.88 (-1.23%) ▼|UNH407.91+1.23 (+0.30%) ▲|UNP260.49+0.58 (+0.22%) ▲|UPS106.18-1.06 (-0.99%) ▼|USB59.74+1.06 (+1.81%) ▲|V331.10+4.50 (+1.38%) ▲|VZ46.60+1.24 (+2.73%) ▲|WFC83.83-0.01 (-0.01%) ▼|WMT119.53+2.35 (+2.01%) ▲|XOM140.15+1.68 (+1.21%) ▲|AAPL299.11+2.10 (+0.71%) ▲|ABBV234.85+4.84 (+2.10%) ▲|ABT90.75+2.92 (+3.32%) ▲|ACN126.82+1.99 (+1.59%) ▲|ADBE199.47+4.57 (+2.34%) ▲|AMAT586.25-53.93 (-8.42%) ▼|AMD520.90-30.73 (-5.57%) ▼|AMGN347.78+3.06 (+0.89%) ▲|AMT178.42+1.99 (+1.13%) ▲|AMZN234.44+1.65 (+0.71%) ▲|AVGO383.75-8.39 (-2.14%) ▼|AXP337.06-1.01 (-0.30%) ▼|BA218.49-2.34 (-1.06%) ▼|BAC57.79+0.42 (+0.72%) ▲|BKNG169.51+1.74 (+1.04%) ▲|BLK1,020.11-31.64 (-3.01%) ▼|BMY55.68+0.98 (+1.79%) ▲|BNY147.89+1.45 (+0.99%) ▲|BRK-B493.60+4.91 (+1.00%) ▲|C145.37-0.30 (-0.21%) ▼|CAT989.58-32.71 (-3.20%) ▼|CL91.38+2.71 (+3.05%) ▲|CMCSA22.89+0.57 (+2.53%) ▲|COF198.39-2.31 (-1.15%) ▼|COP110.28+0.58 (+0.52%) ▲|COST961.01+9.66 (+1.02%) ▲|CRM154.87+4.75 (+3.16%) ▲|CSCO121.81+0.28 (+0.23%) ▲|CVS101.33+0.03 (+0.03%) ▲|CVX176.14+1.08 (+0.61%) ▲|DE598.59+0.00 (+0.00%) ▲|DHR178.54+0.35 (+0.20%) ▲|DIS103.44+0.99 (+0.96%) ▲|DUK125.06+1.54 (+1.25%) ▲|EMR144.51-5.71 (-3.80%) ▼|FDX323.30-5.48 (-1.67%) ▼|GD349.10+5.74 (+1.67%) ▲|GE357.08+1.96 (+0.55%) ▲|GEV1,048.85-78.74 (-6.98%) ▼|GILD125.78+0.91 (+0.73%) ▲|GM80.08-0.35 (-0.44%) ▼|GOOG346.84-1.95 (-0.56%) ▼|GOOGL347.35-2.21 (-0.63%) ▼|GS1,099.08-7.29 (-0.66%) ▼|HD325.50-1.13 (-0.34%) ▼|HON224.66-3.46 (-1.51%) ▼|IBM265.84+13.62 (+5.40%) ▲|INTC133.70-7.24 (-5.14%) ▼|INTU260.76+2.99 (+1.16%) ▲|ISRG401.54-1.42 (-0.35%) ▼|JNJ237.14+5.85 (+2.53%) ▲|JPM334.13+2.65 (+0.80%) ▲|KO79.93+0.40 (+0.50%) ▲|LIN517.00+0.29 (+0.06%) ▲|LLY1,104.37+2.29 (+0.21%) ▲|LMT502.25+8.65 (+1.75%) ▲|LOW214.90+0.50 (+0.23%) ▲|LRCX370.97-38.57 (-9.42%) ▼|MA488.32+4.23 (+0.87%) ▲|MCD271.75+1.65 (+0.61%) ▲|MDLZ60.66+1.15 (+1.92%) ▲|MDT80.36+1.09 (+1.38%) ▲|META564.45+0.60 (+0.11%) ▲|MMM162.40-0.82 (-0.50%) ▼|MO71.12+1.61 (+2.32%) ▲|MRK118.74+3.26 (+2.82%) ▲|MS227.48+0.39 (+0.17%) ▲|MSFT372.72+5.38 (+1.46%) ▲|MU1,072.68-138.70 (-11.45%) ▼|NEE86.58+0.50 (+0.58%) ▲|NFLX73.19+0.31 (+0.42%) ▲|NKE42.94-0.25 (-0.58%) ▼|NOW97.36+4.35 (+4.67%) ▲|NVDA201.83-6.82 (-3.27%) ▼|ORCL168.27-6.80 (-3.88%) ▼|PEP141.06+0.35 (+0.25%) ▲|PFE25.01-0.08 (-0.30%) ▼|PG150.60+2.92 (+1.98%) ▲|PLTR118.86-0.64 (-0.54%) ▼|PM177.91+4.74 (+2.74%) ▲|QCOM201.15-20.75 (-9.35%) ▼|RTX184.92+3.09 (+1.70%) ▲|SBUX100.89+0.74 (+0.74%) ▲|SCHW93.03+1.00 (+1.09%) ▲|SO94.60+1.17 (+1.25%) ▲|SPG216.71+2.14 (+1.00%) ▲|T22.87+0.77 (+3.48%) ▲|TMO466.82+2.81 (+0.61%) ▲|TMUS183.26+3.20 (+1.78%) ▲|TSLA384.06-20.99 (-5.18%) ▼|TXN302.80-29.48 (-8.87%) ▼|UBER70.55-0.88 (-1.23%) ▼|UNH407.91+1.23 (+0.30%) ▲|UNP260.49+0.58 (+0.22%) ▲|UPS106.18-1.06 (-0.99%) ▼|USB59.74+1.06 (+1.81%) ▲|V331.10+4.50 (+1.38%) ▲|VZ46.60+1.24 (+2.73%) ▲|WFC83.83-0.01 (-0.01%) ▼|WMT119.53+2.35 (+2.01%) ▲|XOM140.15+1.68 (+1.21%) ▲|
20.6 C
New York
Tuesday, June 23, 2026

Tag: therapeutics

newssourceFORcompanyinformationcontent1marketreleases

Pomerantz Law Firm Announces the Filing of a Class Action Against PepGen Inc. and Certain Officers – PEPG

NEW YORK, June 22, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against PepGen Inc. ("PepGen" or the "Company")...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. – PTCT

NEW YORK, June 22, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ: PTCT).  Such...

Abvance Therapeutics Announces Presentation of Human Clinical Data at the 85th Scientific Sessions of the American Diabetes Association

Abvance presents first-in-human data on insulin-glucagon co-dosing in T1D, demonstrating a novel approach to help prevent hypoglycemia

Saudi Arabia Concludes Landmark BIO 2025 Debut as Kingdom Opens Doors to Global Biotech Collaboration

From genomics to regulatory innovation, the Kingdom’s presence in Boston establishes it as a major partner in global health science 
From genomics to regulatory innovation, the Kingdom’s presence in Boston establishes it as a major partner in global health science

Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin...

SAN FRANCISCO, June 20, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, today announced two upcoming late-breaking poster presentations at the American Diabetes Association 85th Scientific Sessions, being held from June 20-23 in Chicago, IL.

Cirius Therapeutics Announces Positive Data for MPC Inhibitor 0602K Alone and in Combination with Tirzepatide

MPC-inhibitor 0602K shows significant preservation of lean mass & increased muscle function combined with tirzepatide in pre-clinical DIO models0602K shows profound beneficial transformation of...

Inozyme Pharma, Inc. Announces Postponement of 2025 Annual Meeting of Stockholders

BOSTON, June 20, 2025 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) today announced that it has postponed its 2025 Annual Meeting of Stockholders (the “Annual Meeting”), which was scheduled to be held on June 25, 2025, in light of the previously announced acquisition (the “Acquisition”) by BioMarin Pharmaceutical Inc. (“BioMarin”).

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NOVATO, Calif., June 20, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 48,731 restricted stock units of the company’s common stock to 26 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of June 16, 2025, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).

HLS Therapeutics Reports Annual Meeting Results

TORONTO, June 20, 2025 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on addressing unmet needs in the...

AIM ImmunoTech Announces NYSE American Notice of Noncompliance With Minimum Stockholders’ Equity Requirements

NYSE American previously issued similar warning for same matter and issued the new notice because the deficiency remains as of March 31, 2025

ArriVent Announces Investor Event on Firmonertinib Path Forward for EGFR PACC Mutant NSCLC

Virtual webinar on June 23, 2025 at 8:00 am ET 
Virtual webinar on June 23, 2025 at 8:00 am ET

Larimar Therapeutics Announces Regulatory Update Call on the Nomlabofusp Program for the Treatment of Friedreich’s Ataxia

Conference call and webcast on Monday, June 23, 2025 at 8:00 am EDT 
Conference call and webcast on Monday, June 23, 2025 at 8:00 am EDT

Wave Life Sciences Announces Oral Presentation of Preclinical Data Supporting WVE-007’s Mechanism (INHBE) to Reduce Fat, Preserve Muscle, and Induce Healthy Weight Loss at...

Presentation to highlight WVE-007 (INHBE GalNAc-siRNA) as a potential novel and unique obesity treatment leading to healthy weight loss and supporting preclinical data demonstrating potent and durable reduction in Activin E resulting in fat loss with muscle preservation

Halozyme Announces argenx Received European Commission Approval for VYVGART® Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

SC injection of VYVGART® is available as a vial or prefilled syringe and can be administered by a patient, caregiver, or healthcare professional SAN DIEGO,...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsTherapeutics

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers